Directors & Executives
Richard Rendell
Chief Executive Officer
Richard was covered in Forbes magazine where he highlighted his experience in modern precision medicine and explained that it’s now possible to tailor treatments for cancer, heart disease, stroke and other serious diseases by analysing what makes some patients respond better than others. Richard has worked with distinguished scientists and medical practitioners at the frontlines of healthcare. He believes a comprehensive approach to risk, prevention, diagnosis and treatment requires easy-to-use rapid deployment medical devices that can acquire key biometric data. When these data are coupled with molecular DNA data, we will significantly improve the outcomes of those with these diseases. Delivering these benefits requires intelligent software technology to interpret the clinical implications of these diverse information sources. Ultimately, patient outcomes will improve by predicting and preventing serious diseases, and ensuring the right treatments are available with a higher degree of confidence that the treatments are effective.
This potential impact on healthcare inspires and drives Richard’s deep personal commitment to deliver his vision through Biosignals Diagnostics. Richard draws on a unique set of skills and experience from 15 years of board and CEO roles with medical device and precision medicine companies. Prior to medical technology company involvement, Richard had a long executive career at Oracle Corporation with global responsibilities for products with $100M+ revenues. Richard also founded the advisory board for iSelect and was their CIO when listed on the ASX in June 2013.
Dr. Stephan Foy
Cardiologist & Non-Executive Director
A graduate of University of Otago, Stephan gained his post-graduate Doctor of Medicine by research work at The Princess Margaret Hospital, Christchurch, NZ. After completing his Interventional Fellowship (Percutaneous Coronary Interventions) at Royal Perth Hospital, WA, Stephan was appointed as Consultant Cardiologist at Launceston General Hospital, Tasmania. Stephan’s expertise in invasive cardiac techniques led him to establish the invasive cardiac services at Launceston General Hospital. He implemented the hospital’s cardiac catheterisation and permanent pacemaker implantation services. Stephan had a leading role in the development and implementation of the Cardiac Services at St John of God Geelong Hospital. He has been a key advisor to the hospital’s Cardiac Catheterisation and Interventional Cardiology programmes and Cardiac Care Unit, culminating in his vital role in brokering the hospital’s Cardiac Surgery programme. Stephan’s professional affiliations include Fellow Royal Australasian College of Physicians and Fellow Cardiac Society of Australia and New Zealand. Stephan is an Adjunct Clinical Associate Professor at University of Notre Dame Australia and is an active clinical coordinator and tutor for the UNDA Melbourne Clinical School.
Advisors
Lexie Qin
Co-Founder & Advisor
Lexie is a highly experienced Biomedical Engineer, covering the end-to-end process of developing medical devices that includes Intellectual Property strategy, regulatory strategy and commercialisation strategy. Lexie has a Bachelor of Biomedical Engineering, from Beijing University of Technology and a Master of Biomedical Engineering from University of Melbourne. Lexie is also a certified English – Chinese translator.
Lexie contributed to initial requirements, established development and manufacturing for the Biosignals Diagnostics ecgme device in China. Her language skills continue to drive Biosignals Diagnostics collaborations with PRC based technology businesses. Lexie is a key contributor to the design and development of our future flagship product (the advanced multi-function monitor).
David Page
Corporate Advisor - International Commercialisation
Dr David Page has translated a long career spanning internal Medicine, Critical Care and Anaesthesiology into advisory roles within the Bio/ MedTech sector and the Capital Raise industry. Having graduated from the Australian Institute of Company Directors, held a directorship in a biotech startup, worked with Eaton Square and now Vitti Capital, David brings a mixture of governance and business experience and skills, whilst also intimately understanding BiosignalsDx technology. GAICD, MBBS, FANZCA
A/Prof. Cheng-Hon Yap
Cardiothoracic Surgeon
Over 50 peer reviewed publications Proctor and instructor incl. Robotic surgery University of Melbourne, Deakin, Monash.
Dr. Ramathan Parameswaran
Consultant Cardiologist
St John if God Geelong Hospital and University Hospital Geelong. CANZ and NHMRC scholarships. Complex cardiac patients, ablations, implants, devices.
Renee Ge
AI and Data Sciences Engineer
Renee is a competent young professional bringing 2 years of practical experience, in acquiring, interpreting and analysing data in a fast-paced environment to deliver complex data analysis outcomes including predictive modelling. Renee has extensive skills in AI languages such as Python and R with deep understanding of the application of machine learning in the clinical healthcare context. Renee is currently working on a major project at Monash University ”Monitoring health and wellbeing of seniors using unobstructive sensors” where she has developed computational models for the automatic continuous assessment of functional decline and onset of medical conditions. Renee is a certified English – Chinese translator.